Is Blujepa Right for You? Latest FDA Treatment For UUTI in 2025
Blujepa (gepotidacin) FDA approval was granted on March 25, 2025, to GSK GlaxoSmithKline. Its launch…
News
FDA Approved AQNEURSA Ushers In New Hope For Niemann-Pick Disease Type C Patients
In a landmark decision, the U.S. Food and Drug Administration (FDA) has approved AQNEURSA™ (levacetylleucine), the…
Will Vimseltinib Be the Miracle Cure TGCT Patients Have Prayed For?
In the world of rare disease therapeutics, Vimseltinib has emerged as a groundbreaking oral kinase inhibitor. This…
Is Grafapex Worth It in 2025? Pros, Cons, and Clinical Trial
In January 2025, the FDA approved Grafapex™ (treosulfan) in combination with fludarabine as a conditioning…
Gomekli (Mirdametinib): Hope for Inoperable NF1 Cases
Gomekli™ (mirdametinib) has emerged as a significant advancement in the treatment of neurofibromatosis type 1…
Is Alyftrek Drug Heralding a New Era in Cystic Fibrosis Treatment?
The Alyftrek drug, a groundbreaking once-daily triple-combination therapy, received U.S. Food and Drug Administration (FDA) approval…
Datroway: 37% Reduction In The Risk Of Death VS Chemotherapy
Based on the TROPION-Breast01 trial, Daiichi Sankyo and AstraZeneca’s DATROWAY was approved for the first…
6 Must-Know Facts About Briviact for Partial-Onset Seizures
Epilepsy is a chronic neurological disorder that affects an estimated 65 million people worldwide. Briviact…
Akynzeo Capsule | One Capsule, Dual Protection
Akynzeo capsule is an FDA-approved antiemetic medication specifically designed to address both acute and delayed…
Discover Briumvi Uses, Dosage, and Side Effects
NEW YORK, April 8, 2025 (GLOBE NEWSWIRE) — TG Therapeutics, Inc.(TGTX) announced today that it…
Copyright@ 2016-2024 Hong Kong Deng Yue Med Al Rights